Outcome parameters for trials in atrial fibrillation: executive summary. - Wikidata - awgldk - TriplyDB

Outcome parameters for trials in atrial fibrillation: executive summary.

Outcome parameters for trials in atrial fibrillation: executive summary.

http://www.wikidata.org/entity/Q34583339

about

Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation Oral anticoagulants versus antiplatelet therapy for preventing stroke and systemic embolic events in patients with atrial fibrillation Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation Symptoms In Atrial Fibrillation: A Contemporary Review And Future Directions Computational mapping identifies localized mechanisms for ablation of atrial fibrillation.Clinical characteristics and outcomes of atrial fibrillation and flutter at the Aga Khan University Hospital, Nairobi.Can we improve outcomes in AF patients by early therapy?The COMET Handbook: version 1.0.Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making Efficacy of adjunctive ablation of complex fractionated atrial electrograms and pulmonary vein isolation for the treatment of atrial fibrillation: a meta-analysis of randomized controlled trials.Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'.Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.Excessive supraventricular ectopic activity is indicative of paroxysmal atrial fibrillation in patients with cerebral ischemia Wide circumferential versus individual isolation of pulmonary veins using the endoscopic ablation system.Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins.How often should we monitor for reliable detection of atrial fibrillation recurrence? Efficiency considerations and implications for study design.Genetics of atrial fibrillation and possible implications for ischemic stroke.Adenosine testing after second-generation balloon devices (cryothermal and laser) mediated pulmonary vein ablation for atrial fibrillation.Assessment of CHADS2 and CHA 2DS 2-VASc scores in obstructive sleep apnea patients with atrial fibrillation.Association of the CHADS2 and CHA 2DS 2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients.Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007.How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?Development and validation of a new Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia (ASTA) with focus on symptom burden.Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre stud Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study.Long-term results of minimally invasive stand-alone bi-atrial surgical ablation with a bipolar ablation device for persistent and longstanding persistent AF: a single-center case series of 91 patients.Design and rationale of the PRAGUE-12 trial: a large, prospective, randomized, multicenter trial that compares cardiac surgery with left atrial surgical ablation with cardiac surgery without ablation in patients with coronary and/or valvular heart d Prevalence and Predisposing Factors of Atrial Fibrillation in a Multi-Ethnic Society: The Impact of Racial Differences in Bahrain.Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.The Optimal Treatment For Atrial Fibrillation In Less Developed Countries.Long-term outcomes after ablation of persistent atrial fibrillation: an observational study over 6 years.Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral-Anticoagulation-Naïve Patients With Atrial Fibrillation: A Randomized Trial Validity and reliability of a new, short symptom rating scale in patients with persistent atrial fibrillation.Emergency Department Readmission in Elderly Patients After Acute Rhythm or Rate Control Treatment for Atrial Fibrillation.Stroke And Bleeding Risk Assessment: Where Are We Now?One-Shot Ablation For PV Isolation.Catheter Ablation of Atrial Fibrillation in Females.Risk Alteration for Atrial Fibrillation with DifferentAntihypertensive Drugs.

P2860

Q24197843-D0FB8318-7BCF-43FB-878C-F7447D604262 Q24200497-E8664385-B843-4179-9E1F-1319E41D8C53 Q24203797-13BE2BA8-EF1C-435F-9D2F-88917B9FD9D2 Q24234397-9B74EF2D-07D4-4882-AC78-82600C9C2527 Q28070025-3DE280D2-EC63-4E74-8112-AE60CF58FB2A Q31103589-4652776F-D405-4C89-A123-5623339567A1 Q33162693-9B3B03C0-84C1-4D70-9D05-27CAF0A5A16C Q33516708-FD3A35B7-E451-4DCC-9474-B47DB5FCFB53 Q33877196-E27D6752-2ED5-4CED-AA65-347D021761AB Q33949571-C098CD90-3994-4926-85DB-51E7CF88046F Q34505587-9892AE2D-AA93-4555-AE59-01BC59ABD3FA Q34609020-182D8F6D-AD07-4AE2-8A22-70A8D57E67E3 Q34737465-FE49BCD9-10C4-4C53-99DF-F95255EB4B53 Q34807752-3C27EEAE-4FF7-495D-9312-74BD1587FAF6 Q35044455-F486AF46-31E5-4FE1-A15D-790D8BE946C2 Q35099851-CDA9BA9D-01D8-4BEA-A078-EEFA340586C5 Q35101086-E384F51B-7745-4211-9FF1-6D5100784BB5 Q35142380-4AD3721E-FA4B-4363-9FF1-99F7B1977766 Q35205067-D3B043DA-F39D-48EC-891C-5AFEBD568B01 Q35597696-0475B3C5-C396-423B-84CE-B7455201AFA6 Q35768680-2F68BB42-F51A-4255-A8E9-01097A2F0E41 Q35901629-616CFF32-178C-48A6-9CE8-BF6B5A144E31 Q35903784-0351DFAD-033E-4DFB-82F8-760FFA3E6F82 Q36021753-8AE7B0B4-4306-4564-A4E6-9C6E78357E4D Q36198393-8E4A4836-9551-44CC-9E76-BB2ED84CB3F3 Q36361300-EEED8668-FE8C-4C60-ABCE-A7D2587968B5 Q36375674-BAADEFBE-BB17-4FB5-9736-9978F543A0B6 Q36529411-39EBD901-4135-48E2-AB42-0597023FE847 Q36587561-D536D79B-E16C-4991-AEDB-AAA64B7C638D Q36617899-458AFC51-5B4C-42EF-8206-1286DF055678 Q36841028-A334C30D-CD9F-4829-8E76-443FA54FA86E Q37115550-B80AB72C-2860-4B44-B159-1FAEAC4AB41D Q37156455-29946075-C187-4664-85AB-06A9C1FE64AA Q37240792-580F34B2-F070-4A13-BBFC-8D46316C16C6 Q37278794-0BC56704-977E-4993-BAE5-6C2F70846A1B Q37456935-D77F0162-80DF-4ADC-9417-089A9FC442EB Q37469069-F74F2E2C-7944-4317-8D73-50B43216346E Q37469131-ABC8FB92-FD26-486C-9806-4CE43DA97F25 Q37495821-15A17CE7-7F81-4E73-A5AF-7798865F36CA Q37495894-F859282C-9984-4F2A-8A91-9E32D54A0A49

P2860

Outcome parameters for trials in atrial fibrillation: executive summary.

http://www.wikidata.org/entity/Q34583339

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Outcome parameters for trials in atrial fibrillation: executive summary.

@ast

Outcome parameters for trials in atrial fibrillation: executive summary.

@en

Outcome parameters for trials in atrial fibrillation: executive summary.

@nl

type

label

Outcome parameters for trials in atrial fibrillation: executive summary.

@ast

Outcome parameters for trials in atrial fibrillation: executive summary.

@en

Outcome parameters for trials in atrial fibrillation: executive summary.

@nl

prefLabel

Outcome parameters for trials in atrial fibrillation: executive summary.

@ast

Outcome parameters for trials in atrial fibrillation: executive summary.

@en

Outcome parameters for trials in atrial fibrillation: executive summary.

@nl

P1433

Q34583339-35D90991-67C4-40A4-8D32-85D7E9730724

P1476

Q34583339-C5407AD0-F533-4363-B05A-9DBC72237B65

P2093

Q34583339-06D25F4F-E3D8-492F-8D03-780E83162477

Q34583339-06F7535D-E490-450B-B36C-A576EF05B233

Q34583339-0882B804-5C00-410A-993C-6D2AA43D355D

Q34583339-16ED0850-9ACD-4C7E-8320-CA4C7FAF5D54

Q34583339-40DA2A23-CD8B-4CD0-8E08-A55A18253CAF

Q34583339-4534B452-3571-4E8F-B83A-C1F5E4337DE7

Q34583339-46B626DB-0085-4DBE-B60A-E1AB60D00224

Q34583339-5521E268-6416-4987-BD13-BAC70BA38D7B

Q34583339-56266209-3C28-4C2C-977E-A0FEBCAE4B1B

Q34583339-6961B51F-E4B3-4751-9126-DE16CE246A5A

P304

Q34583339-38F93FA2-3434-4DFF-9512-6A7A78154703

P31

Q34583339-E07C4764-C20E-4438-A5B4-F3463CA4C256

P356

Q34583339-F33E569A-061E-4150-8FB1-A74BD04B0749

P433

Q34583339-CC508325-7146-4ECB-B61B-50FF82A870A4

P478

Q34583339-651C3388-3111-4FD7-B41B-5E1EB94A7CA8

P50

Q34583339-25F8F7B9-2589-4FDB-ABC5-6FA0C66261A5

Q34583339-2ffd5d1f-47b4-7052-d2b3-d8fe45dd4380

Q34583339-9F47E2C3-23DA-4111-8FAC-A761ED261E0B

Q34583339-A0F1AA57-A798-4F08-82DD-BDD6B018044C

Q34583339-D0ED8BB7-6DFB-44C8-89A2-F30E5911069B

Q34583339-DCB12327-7FDC-48DD-B9DC-4C2D3080FED7

Q34583339-E45E8666-A1BE-4A0C-AAAD-F6FEE39A2331

Q34583339-F4C99E5E-4A36-45D4-987C-4754274E258B

P577

Q34583339-4B218041-3FF9-4BE2-A5BB-174C3A8D25D0

P5875

Q34583339-5C106D3C-24CA-4508-BD0A-18FCD795C888

P698

Q34583339-61C18B3D-F0AB-4FEC-97CA-A815F06F6EA2

P921

Q34583339-2798296D-4D16-478C-B735-6FF35AC6F367

P356

P1433

European Heart Journal

P1476

Outcome parameters for trials in atrial fibrillation: executive summary.

@en

P2093

Alphons Vincent

http://www.w3.org/2001/XMLSchema#string

Andreas Goette

http://www.w3.org/2001/XMLSchema#string

Bertil Olsson

http://www.w3.org/2001/XMLSchema#string

Elisabeth Svernhage

http://www.w3.org/2001/XMLSchema#string

Gerd Hindricks

http://www.w3.org/2001/XMLSchema#string

Gerhard Steinbeck

http://www.w3.org/2001/XMLSchema#string

Harry Crijns

http://www.w3.org/2001/XMLSchema#string

Jan Tijssen

http://www.w3.org/2001/XMLSchema#string

John Camm

http://www.w3.org/2001/XMLSchema#string

Lukas Kappenberger

http://www.w3.org/2001/XMLSchema#string

P304

2803-2817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHM358

http://www.w3.org/2001/XMLSchema#string

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Karl-Heinz Kuck

Hans-Christoph Diener

Paulus Kirchhof

Gregory Y. H. Lip

Angelo Auricchio

Jeroen Joost Bax

Günter Breithardt

P577

2007-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5946671

http://www.w3.org/2001/XMLSchema#string

P698

17897924

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation